Mga Batayang Estadistika
| CIK | 1408299 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Entia Biosciences, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| February 9, 2019 |
ERGO / Entia Biosciences Inc. FORM 15-12G/A 15-12G/A 1 entiabio201902081512ga.htm FORM 15-12G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15-A CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 000-52864 Entia Biosci |
|
| December 19, 2018 |
ERGO / Entia Biosciences Inc. FORM 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 000-52864 Entia Biosciences, Inc. (Exact name of registrant as specified in |
|
| September 7, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 6, 2018 Entia Biosciences, Inc. |
|
| April 20, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 16, 2018 Entia Biosciences, Inc. |
|
| March 30, 2018 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 30, 2018 Entia Biosciences, Inc. |
|
| December 4, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Of Earliest Event Reported): November 28, 2017 Entia Biosciences, Inc. |
|
| May 19, 2017 |
ERGO / Entia Biosciences Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016. OR ☐ TRANSITION REPORT PURSUANT SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . 000-52864 (Commission file number) Entia Biosciences, Inc. (Ex |
|
| May 15, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K o Form 20-F o Form 11-K ? Form 10-Q o Form N-SAR o Form N-CSR For Period Ended: March 31, 2017 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| March 31, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K o Form 20-F o Form 11-K ? Form 10-Q o Form N-SAR o Form N-CSR For Period Ended: December 31, 2016 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| March 2, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| February 24, 2017 |
EXHIBIT 99.2 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in the places marked ?[***]? and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. LICENSE AGREEMENT This LICENSE AGREEMENT (the ?Agreement?) is dated as of the date of the last signature below (the ?Effective Date?), b |
|
| February 24, 2017 |
CONTRACT FOR THE SALE OF GOODS EXHIBIT 99.3 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in the places marked ?[***]? and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. CONTRACT FOR THE SALE OF GOODS This CONTRACT FOR THE SALE OF GOODS (the ?Agreement?) is dated as of the date of the last signature below |
|
| February 24, 2017 |
– for release February 24, 2017 EXHIBIT 99.1 Press Release ? for release February 24, 2017 Entia Biosciences, Inc. (OTCQB: ERGO) Enters into Exclusive Worldwide Licensing Agreement for its GROH Beauty Products Line PORTLAND, Oregon - ( GlobeNewswire ) ?Entia Biosciences, Inc. (OTCQB: ERGO) announced that it has licensed to GROH BEAUTY CORP of Deerfield Beach, Florida, the exclusive worldwide rights to manufacture and distribute |
|
| February 24, 2017 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 21, 2017 Entia Biosciences, Inc. |
|
| February 17, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| December 9, 2016 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Of Earliest Event Reported): December 9, 2016 Entia Biosciences, Inc. |
|
| November 14, 2016 |
Entia Biosciences 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended September 30, 2016 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-52864 Entia Bioscience |
|
| November 2, 2016 |
– for release November 2, 2016 EXHIBIT 99.1 Press Release ? for release November 2, 2016 Entia Biosciences, Inc. (OTCQB: ERGO) Receives Notification of the Grant of European Patent it has Exclusively Licensed for Identifying the Ergothioneine Transporter and its Therapeutic Uses PORTLAND, Oregon - ( GlobeNewswire) ?Entia Biosciences, Inc. (OTCQB: ERGO) has been informed that the European Patent Office has granted European Paten |
|
| November 2, 2016 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Of Earliest Event Reported): October 27, 2016 Entia Biosciences, Inc. |
|
| September 29, 2016 |
Entia Biosciences 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended June 30, 2016 ? TRANSITION REPORT PURSUANT SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-52864 Entia Biosciences, Inc. ( |
|
| September 28, 2016 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Of Earliest Event Reported): September 22, 2016 Entia Biosciences, Inc. |
|
| August 25, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Of Earliest Event Reported): August 21, 2016 Entia Biosciences, Inc. |
|
| August 25, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Of Earliest Event Reported): August 21, 2016 Entia Biosciences, Inc. |
|
| August 16, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K o Form 20-F o Form 11-K ? Form 10-Q o Form N-SAR o Form N-CSR For Period Ended: June 30, 2016 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| August 16, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K o Form 20-F o Form 11-K ? Form 10-Q o Form N-SAR o Form N-CSR For Period Ended: June 30, 2016 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| May 16, 2016 |
Entia Biosciences 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period ended March 31, 2016 ? TRANSITION REPORT PURSUANT SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-52864 Entia Biosciences, Inc. |
|
| April 14, 2016 |
AMENDED AND RESTATED ARTICLES OF INCORPORATION OF ENTIA BIOSCIENCES, INC. Exhibit 3.1 AMENDED AND RESTATED ARTICLES OF INCORPORATION OF ENTIA BIOSCIENCES, INC. 1. Name of Corporation The name of the Corporation is “ENTIA BIOSCIENCES, INC.” 2. Registered Agent for Service of Process The name of the Corporation’s registered agent is Ryan Edington, 4129 Galapagos Avenue, North Las Vegas, Nevada 89084. 3. Authorized Stock A. General. The Corporation shall be authorized to i |
|
| April 13, 2016 |
Entia Biosciences 10-K (Annual Report) entiabiosciences10k123115.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015. OR o TRANSITION REPORT PURSUANT SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . 000-52864 (Commission file numbe |
|
| March 30, 2016 |
entiabio-nt10k123115.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form N-SAR o Form N-CSR For Period Ended: December 31, 2015 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transiti |
|
| February 19, 2016 |
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8-K 1 entiabiosciences8k021916.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Of Earliest Event Reported): December 3, 2015 Entia Biosciences, Inc. (Exact name of registrant as specified in charter) Commission File Number : 000-52864 Nevada 26-0561199 ( |
|
| February 16, 2016 |
ERGO / Entia Biosciences Inc. / TAM CHEUK HO - SC 13G/A Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— SCHEDULE 13G ——————— Under the Securities Exchange Act of 1934 (Amendment No. 1)* Entia Biosciences, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 29384E104 (CUSIP Number) December 31, 2015 (Date of Event which Requires Filing of this Statement) Check the appropriate box to d |
|
| February 16, 2016 |
ERGO / Entia Biosciences Inc. / WONG WAH ON EDWARD - SC 13G/A Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— SCHEDULE 13G ——————— Under the Securities Exchange Act of 1934 (Amendment No. 1)* Entia Biosciences, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 29384E104 (CUSIP Number) December 31, 2015 (Date of Event which Requires Filing of this Statement) Check the appropriate box to d |
|
| December 15, 2015 |
entiabio-def14a121515.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by |
|
| December 11, 2015 |
ERGO / Entia Biosciences Inc. / TAM CHEUK HO - SC 13G Passive Investment SC 13G 1 tam13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— SCHEDULE 13G ——————— Under the Securities Exchange Act of 1934 (Amendment No. )* Entia Biosciences, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 29384E104 (CUSIP Number) December 31, 2014 (Date of Event which Requires Filing of this Statement) Check the a |
|
| December 11, 2015 |
ERGO / Entia Biosciences Inc. / WONG WAH ON EDWARD - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— SCHEDULE 13G ——————— Under the Securities Exchange Act of 1934 (Amendment No. )* Entia Biosciences, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 29384E104 (CUSIP Number) December 31, 2014 (Date of Event which Requires Filing of this Statement) Check the appropriate box to de |
|
| December 4, 2015 |
entiabiosciences8k120315.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Of Earliest Event Reported): December 3, 2015 Entia Biosciences, Inc. (Exact name of registrant as specified in charter) Commission File Number: 000-52864 Nevada 26-0561199 (State or ot |
|
| November 25, 2015 |
entiabio-pre14a112415.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by |
|
| October 8, 2015 |
entiabiosciences8k100815.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Of Earliest Event Reported): October 2, 2015 Entia Biosciences, Inc. (Exact name of registrant as specified in charter) Commission File Number: 000-52864 Nevada 26-0561199 (State or oth |
|
| October 8, 2015 |
ex10-2.htm Exhibit 10.2 EMPLOYMENT AGREEMENT This employment agreement (the ?Agreement?) is effective as of October 1, 2015 between Entia Biosciences, Inc, a Nevada corporation (?ERGO?), and Marvin S. Hausman MD, an individual resident of Oregon (?Executive?). RECITALS Whereas, Executive has acquired special skills and abilities and an extensive background in and knowledge of ERGO?s business and t |
|
| October 8, 2015 |
10.1 Employment Agreement between Entia Biosciences, Inc. and Timothy Timmins dated October 2, 2015. ex10-1.htm Exhibit 10.1 EMPLOYMENT AGREEMENT This employment agreement (the ?Agreement?) is effective as of October 1, 2015 between Entia Biosciences, Inc., a Nevada corporation (?ERGO? or "the Company"), and Timothy A. Timmins, an individual resident of Oregon (?Executive?). RECITALS Whereas, Executive has acquired special skills and abilities and an extensive background in and knowledge of ERGO? |
|
| September 8, 2015 |
ex10-1.htm EXHIBIT 10.1 SEPARATION AGREEMENT AND RELEASE THIS SEPARATION AGREEMENT AND RELEASE ("Separation Agreement") is made and entered into by and between Devin Andres ("Andres") and Entia Biosciences, Inc., a Nevada corporation ("Entia"), including its predecessor, Total Nutraceutical Solutions, Inc., a Nevada corporation ("TNS") (Entia and TNS, including all affiliates and subsidiaries, wil |
|
| September 8, 2015 |
entiabiosciences8k090815.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Of Earliest Event Reported): September 2, 2015 Entia Biosciences, Inc. (Exact name of registrant as specified in charter) Commission File Number: 000-52864 Nevada 26-0561199 (State or o |
|
| September 4, 2015 |
Entia Biosciences, Inc. 2010 Stock Incentive Plan, as amended and restated ex99-1.htm Exhibit 99.1 ENTIA BIOSCIENCES, INC. 2010 Stock Incentive Plan Amended and Restated Adopted by the Board of Directors on September 17, 2010 Approval by the shareholders on October 21, 2010 Amended and restated February 15, 2012 Amended and restated December 17, 2013 SECTION 1. INTRODUCTION. The Board adopted the Plan on September 17, 2010 (effective October 21, 2010 upon approval by the |
|
| September 4, 2015 |
entiabiosciences-s8090315.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ENTIA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 26-0561199 (State or other jurisdiction (IRS Employer of incorporation or organization) Identification No.) 13565 SW Tualatin Sherwood Rd #800, She |
|
| August 13, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Of Earliest Event Reported): August 12, 2015 Entia Biosciences, Inc. |
|
| August 13, 2015 |
10.1 Employment Agreement between Entia Biosciences, Inc. and Carl Johnson dated August 12, 2015. ex10-1.htm EXHIBIT 10.1 EMPLOYMENT AGREEMENT This employment agreement (the ?Agreement?) is effective as of August 12, 2015 between Entia Biosciences, Inc, a Nevada corporation (?ERGO?), and Carl Johnson, an individual resident of Arizona (?Executive?). RECITALS Whereas, Executive has acquired special skills and abilities and an extensive background in and knowledge of ERGO?s business and the indu |
|
| August 12, 2015 |
entiabiosciences8k081215.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Of Earliest Event Reported): July 27, 2015 Entia Biosciences, Inc. (Exact name of registrant as specified in charter) Commission File Number: 000-52864 Nevada 26-0561199 (State or other |
|
| May 4, 2015 |
Financial Statements and Exhibits, Other Events entiabiosciences8k050415.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Of Earliest Event Reported): April 28, 2015 Entia Biosciences, Inc. (Exact name of registrant as specified in charter) Commission File Number: 000-52864 Nevada 26-0561199 (State or othe |
|
| February 26, 2015 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Of Earliest Event Reported): February 4, 2014 Entia Biosciences, Inc. |
|
| February 24, 2015 |
Entia Biosciences Updates Investors with an Annual Shareholder Letter EXHIBIT 99.1 Entia Biosciences Updates Investors with an Annual Shareholder Letter SHERWOOD, OR, United States, via ETELIGIS INC., 02/24/2015 - - Entia Biosciences, Inc. (OTCQB: ERGO), an emerging leader in the field of Nutrigenomics, released today the following Annual Shareholder Letter by Marvin S. Hausman MD, Chairman and CEO. Dear Shareholders, Friends and GROH® Product Clients: In a few word |
|
| February 24, 2015 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Of Earliest Event Reported): February 24, 2015 Entia Biosciences, Inc. |
|
| February 9, 2015 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Of Earliest Event Reported): February 4, 2015 Entia Biosciences, Inc. |
|
| January 15, 2015 |
Extension Agreement between Entia Biosciences, Inc. and Arthur C. Piculell executed January 10, 2015 Exhibit 10.1 December 26th, 2014 Arthur C. Piculell Jr. and Marvin S. Hausman, CEO Entia Biosciences Inc. hereby extend Exhibit A attached hereto and made a part hereof as if fully set out herein. 1. This agreement will be extended for one year from the above date with the interest rate of 8% from the original date of note August 13, 2013. 2. In addition thereto Arthur C. Piculell Jr. will also re |
|
| January 15, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Of Earliest Event Reported): January 10, 2015 Entia Biosciences, Inc. |
|
| January 5, 2015 |
COMMON STOCK AND WARRANT PURCHASE AGREEMENT ENTIA BIOSCIENCES, INC. EXHIBIT 10.2 COMMON STOCK AND WARRANT PURCHASE AGREEMENT ENTIA BIOSCIENCES, INC. THIS COMMON STOCK AND WARRANT PURCHASE AGREEMENT is entered into as of the latter of the dates on which this agreement was signed the “Agreement”), by and among Entia Biosciences, Inc., a Nevada corporation (the “Company”) and Delta Group Investments Limited (the “Purchaser”). The parties hereby agree as follows: ARTI |
|
| January 5, 2015 |
THIRD AMENDMENT TO PROMISSORY NOTE DELTA GROUP INVESTMENTS LIMITED EXHIBIT 10.1 THIRD AMENDMENT TO PROMISSORY NOTE DELTA GROUP INVESTMENTS LIMITED The following terms set forth the third amendment to the Promissory Note dated January 26, 2011 (the Agreement) between Delta Group Investments Limited (the Holder) and Entia Biosciences, Inc. (the Company). WHEREAS, on January 26, 2011 the Holder and the Company entered into a Promissory Note in the principal amount o |
|
| January 5, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Of Earliest Event Reported): December 15, 2014 Entia Biosciences, Inc. |
|
| January 5, 2015 |
EXHIBIT 10.3 |
|
| January 5, 2015 |
EXHIBIT 10.4 |
|
| December 22, 2014 |
ERGO / Entia Biosciences Inc. DEF 14A - - ERGO DEF 14A 12/19/14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] Definitive P |
|
| November 14, 2014 |
EXHIBIT 10.2 |
|
| November 14, 2014 |
EXHIBIT 10.1 |
|
| November 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Of Earliest Event Reported): September 25, 2014 Entia Biosciences, Inc. |
|
| September 11, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Of Earliest Event Reported): September 9, 2014 Entia Biosciences, Inc. |
|
| September 11, 2014 |
PROFESSIONAL DISTRIBUTOR AGREEMENT EXHIBIT 10.1 PROFESSIONAL DISTRIBUTOR AGREEMENT THIS AGREEMENT is made as of September 1st, 2014 between Total Nutraceutical Solutions, Inc. (hereafter “Manufacturer”), having its principal office at 13565 SW Tualatin-Sherwood Rd, Suite 800, Sherwood, OR 97140 and Shooting Starzz, LLC (hereafter “Distributor”), having its principal office at 1590 NW 27th Ave Ste. 2, Pompano, Beach FL 33069. RECITA |
|
| August 15, 2014 |
ERGO / Entia Biosciences Inc. NT 10-Q - - ERGO NT 10-Q 06/30/14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC FILE NUMBER 000-52864 FORM 12b-25 CUSIP NUMBER 89153Y 103 NOTIFICATION OF LATE FILING (Check one): [ ]Form 10-K [ ]Form 20-F [ ]Form 11-K [X]Form 10-Q [ ]Form N-SAR [ ]Form N-CSR For Period Ended: June 30, 2014 Transition Report on Form 10-K Transition Report on Form 20-F Transition Report on Form 11-K Transition Report on |
|
| August 14, 2014 |
ERGO / Entia Biosciences Inc. / ASHER ENTERPRISES INC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1)* ENTIA BIOSCIENCES, INC. (Name of issuer) Common Stock, $0.001 value per share (Title of class of securities) 29384E104 (CUSIP number) August 12, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| May 14, 2014 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Of Earliest Event Reported): April 26, 2014 Entia Biosciences, Inc. |
|
| April 11, 2014 |
ERGO / Entia Biosciences Inc. / ASHER ENTERPRISES INC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. )* ENTIA BIOSCIENCES, INC. (Name of issuer) Common Stock, $0.001 value per share (Title of class of securities) 29384E104 (CUSIP number) April 11, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| March 31, 2014 |
Entia Biosciences ERGO 10-K 12/31/13 (Annual Report) ERGO 10-K 12/31/13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 19, 2013 |
Entia Biosciences Inc. - Noah’s Nutritionals Asset Sales Agreement December, 17th 2013 EXHIBIT 10.2 Entia Biosciences Inc. - Noah’s Nutritionals Asset Sales Agreement December, 17th 2013 THIS AGREEMENT is made and entered into on the 17th of December, 2013 by and between Entia Biosciences, Inc. (“Buyer” or the “Company”) having an address of 13565 SW Tualatin-Sherwood Rd #800, Sherwood, OR 97140 and Noah’s Nutritionals (“Seller” or “Funguys LLC”) having an address of 4032 138th Aven |
|
| December 19, 2013 |
PROMISSORY NOTE $40,000.00 Date: December 17, 2012 EXHIBIT 10.1 PROMISSORY NOTE $40,000.00 Date: December 17, 2012 FOR VALUE RECEIVED, and pursuant to this Promissory Note executed between Philip Sobol (the "Payee") and Entia Biosciences , Inc. (“ENTIA”, the “Company”, the "Payor"), the undersigned, hereinafter referred to as "Payor", unconditionally promises to pay to the order of "Payee", at the following address: 3230 Iredell Lane, Studio City, |
|
| December 19, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Of Earliest Event Reported): December 16, 2013 Entia Biosciences, Inc. |
|
| December 2, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] Definitive P |
|
| November 8, 2013 |
Amendment & Transfer of Promissory Note Mark Wolf EXHIBIT 10.1 Amendment & Transfer of Promissory Note Mark Wolf The following terms set forth the amendment and transfer of the Promissory Note between Mark C. Wolf (“Mr. Wolf” or “Payee”) and Entia Biosciences, Inc. (“Entia” or “Company”) formerly Total Nutraceutical Solutions, Inc. WHEREAS, the promissory note with Mr. Wolf was dated February 18, 2010 in the principal amount of $50,000 with inter |
|
| November 8, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Of Earliest Event Reported): June 20, 2013 Entia Biosciences, Inc. |
|
| November 8, 2013 |
EXHIBIT 99.1 CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK OF ENTIA BIOSCIENCES, INC. AS AMENDED NOVEMBER 4, 2013 ENTIA BIOSCIENCES, INC. (the “Corporation”), a corporation organized in the State of Nevada, DOES HEREBY CERTIFY that, pursuant to authority conferred upon the Board of Directors by the Nevada Revised Statutes Section 78.195, |
|
| July 3, 2013 |
EXHIBIT 10.1 PROMISSORY NOTE $40,000.00 Date: June 11, 2013 FOR VALUE RECEIVED, and pursuant to this Promissory Note executed between Philip Sobol (the Payee) and Entia Biosciences, Inc. (ENTIA, the Payor), the undersigned, hereinafter referred to as Payor, unconditionally promises to pay to the order of Payee, at the following address: 3230 Iredell Lane, Studio City, CA 91604 or at such other pla |
|
| July 3, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Of Earliest Event Reported): June 11, 2013 Entia Biosciences, Inc. |
|
| July 3, 2013 |
SECOND AMENDMENT TO PROMISSORY NOTE DELTA GROUP INVESTMENTS LIMITED EXHIBIT 10.2 SECOND AMENDMENT TO PROMISSORY NOTE DELTA GROUP INVESTMENTS LIMITED The following terms set forth the second amendment to the Promissory Note dated January 26, 2011 between Delta Group Investments Limited (the Holder) and Entia Biosciences, Inc. (the Company). WHEREAS, on January 26, 2011 the Holder and the Company entered into a Promissory Note in the principal amount of $312,500, wi |
|
| June 25, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ENTIA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 26-0561199 (State or other jurisdiction (IRS Employer of incorporation or organization) Identification No.) 13565 SW Tualatin Sherwood Rd #800, Sherwood, OR 97140 (Address of pr |
|
| June 25, 2013 |
ENTIA BIOSCIENCES, INC. 2010 Stock Incentive Plan Amended and Restated EXHIBIT 99.1 ENTIA BIOSCIENCES, INC. 2010 Stock Incentive Plan Amended and Restated Adopted by the Board of Directors on September 17, 2010 Approval by the shareholders on October 21, 2010 Amended and restated May 1, 2013 SECTION 1. INTRODUCTION. The Board adopted the Plan on September 17, 2010 (effective October 21, 2010 upon approval by the stockholders). The Plan was amended and restated on Feb |
|
| May 3, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Of Earliest Event Reported): April 29, 2013 Entia Biosciences, Inc. |
|
| April 15, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] Definitive P |
|
| March 19, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Of Earliest Event Reported): March 12, 2013 Entia Biosciences, Inc. |
|
| November 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC FILE NUMBER 000-52864 FORM 12b-25 CUSIP NUMBER 89153Y 103 NOTIFICATION OF LATE FILING (Check one): [ ]Form 10-K [ ]Form 20-F [ ]Form 11-K [X]Form 10-Q [ ]Form N-SAR [ ]Form N-CSR For Period Ended: September 30, 2012 Transition Report on Form 10-K Transition Report on Form 20-F Transition Report on Form 11-K Transition Repo |
|
| August 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC FILE NUMBER 000-52864 FORM 12b-25 CUSIP NUMBER 89153Y 103 NOTIFICATION OF LATE FILING (Check one): [ ]Form 10-K [ ]Form 20-F [ ]Form 11-K [X]Form 10-Q [ ]Form N-SAR [ ]Form N-CSR For Period Ended: June 30, 2012 Transition Report on Form 10-K Transition Report on Form 20-F Transition Report on Form 11-K Transition Report on |
|
| April 10, 2012 |
COMMERCIAL LEASE THIS LEASE is made and entered into this 23rd day of March, 2012, by and between Lanz Properties, LLC ("Lessor") and Entia Biosciences, Inc. |
|
| April 10, 2012 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Of Earliest Event Reported): April 4, 2011 Entia Biosciences, Inc. |
|
| March 5, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ENTIA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 26-0561199 (State or other jurisdiction (IRS Employer of incorporation or organization) Identification No.) P.O. Box 910 Stevenson, Washington 98648 (Address of principal execut |
|
| March 5, 2012 |
ENTIA BIOSCIENCES, INC. 2010 Stock Incentive Plan Amended and Restated EXHIBIT 99.1 ENTIA BIOSCIENCES, INC. 2010 Stock Incentive Plan Amended and Restated Adopted by the Board of Directors on September 17, 2010 Approval by the shareholders on October 21, 2010 Amended and restated February 15, 2012 SECTION 1. INTRODUCTION. The Board adopted the Plan on September 17, 2010 (effective October 21, 2010 upon approval by the stockholders) and the Plan was amended and restat |
|
| February 16, 2012 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Of Earliest Event Reported): February 15, 2012 Entia Biosciences, Inc. |
|
| January 30, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Of Earliest Event Reported): January 9, 2011 Entia Biosciences, Inc. |
|
| January 30, 2012 |
AMENDED AND RESTATED ARTICLES OF INCORPORATION Article 1 Name of Corporation EXHIBIT 3.1 AMENDED AND RESTATED ARTICLES OF INCORPORATION Article 1 Name of Corporation Entia Biosciences, Inc. Article 2 Resident Agent Name and Street Address Thomas C. Cook, Esq., 500 N. Rainbow, Suite 300, Las Vegas, Nevada 89107 Article 3 Number of Shares Corporation is Authorized to Issue Number of Shares: 150,000,000 Common 5,000,000 Preferred Par Value $0.001 Number of Shares without par |
